Alliant will promote kids' Allegra in U.S.

sanofi U.S. firm Alliant said Monday it has signed a deal with Sanofi-aventis to co-promote allergy drug Allegra in the United States.

Under the terms of the pact Alliant will promote Allegra Oral Suspension to pediatric and pediatric sub-specialty physicians.

"Our core mission is to provide pediatricians with alternatives that meet the unique needs of their patients," said Alliant President Mark Pugh.

Sanofi-aventis got Food and Drug Administration approval in October 2006 for use of the oral suspension to relieve seasonal allergy symptoms in kids aged 2 to 11 and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in kids ages 6 months to 11 years.

source - UPI